Patients with type 2 diabetes who experience hypoglycemia during sulfonylurea treatment are at greater risk for cardiovascular events than those who do not experience hypoglycemia, results of a US study suggest.
Results of a modeling study suggest that timely intensification of oral antidiabetic treatment is associated with a lower risk for complications but a higher risk for hypoglycemia compared with delayed treatment among patients with type 2 diabetes.
Many of the currently available oral anti-diabetic agents have clinically relevant cardiovascular effects. This expert review concludes that optimal approach to the reduction of cardiovascular risk in diabetic patients should focus on aggressive management of the standard cardiovascular risk factors rather than purely on intensive glycemic control.
Xu J & Rajaratnam R. Cardiovasc Diabetol 2017;16:18. doi:10.1186/s12933-017-0499-5
The authors discuss the prevalence of obesity and type 2 diabetes in children and adolescents and summarize published studies on the safety and effectiveness of antihyperglycemic medications in this population.
Akhlaghi F et al. Clin Pharmacokinet 2017; 56: 561–571. doi:10.1007/s40262-016-0472-6
The review discusses pharmacological therapy for gestational diabetes, dealing with safety and efficacy, for both fetal and maternal morbidity consequences; as well as failure and success in establishing appropriate metabolic and glucose control.
Bergel R et al. Curr Diab Rep 2016; 16: 118. doi:10.1007/s11892-016-0802-y
The authors present their experience with a patient with permanent neonatal diabetes, initially misdiagnosed as type 1 diabetes, who was successfully transitioned to oral sulfonylurea therapy after 37 years of insulin dependence.
Arce KM & Pantalone KM. Diabetes Ther 2016; 7: 369–375. doi:10.1007/s13300-016-0171-1